Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 3/20 | 0.32 |
| ▸ | RARB | P10826 | 3/20 | 0.32 |
| ▸ | RARG | P13631 | 3/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072328 | 0.91 | PDK2 (0.35) | CA1CA2HPGDPDK2 | |
| SCHEMBL10072347 | 0.89 | CA1 (0.35) | CA1CA2HPGDRARARARB | |
| SCHEMBL872468 | 0.89 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL10072330 | 0.87 | ALOX5AP (0.35) | CA1CA2PDK2 | |
| SCHEMBL10072331 | 0.86 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL10072339 | 0.85 | HPGD (0.35) | CA1CA2HPGDPDK2KDM4E | |
| SCHEMBL871282 | 0.85 | PDK2 (0.37) | CA1CA2HPGDPDK2KDM4E | |
| SCHEMBL10316194 | 0.84 | TYMS (0.35) | CA1CA2HPGDPDK2KDM4E | |
| SCHEMBL21863425 | 0.83 | PDK2 (0.36) | CA1CA2HPGDPDK2KDM4E | |
| SCHEMBL872236 | 0.83 | RXRA (0.34) | HPGDPDK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | CYP1A2, CYP3A7, CYP2E1 | CA1 2008/4885CA2 1391/4885HPGD 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.